Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies

Development of a Microsampling Approach for Personalized Monitoring of Kinase Inhibitor Targeted Therapies

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05598788

Acronym

MISTIK

Enrollment

160

Registered

2022-10-28

Start date

2023-03-03

Completion date

2025-04-24

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

Keywords

ORAL CHEMOTHERAPIES, AT HOME THERAPEUTIC DRUG MONITORING, MICROSAMPLING STRATEGY, CONCENTRATION EFFECT RELATIONSHIP, PERSONALIZED MEDICINE

Brief summary

The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.

Detailed description

The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib. Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.

Interventions

OTHERMeasurement of drug concentrations

Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients treated with one of the 9 drugs concerned by the study : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib * person who does not object to their participation in the research

Exclusion criteria

* Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty

Design outcomes

Primary

Measure	Time frame	Description
Comparison of venous blood vs VAMS concentrations	1 day	Comparison of drug concentrations measured from the venous blood samples with concentrations measured from VAMS

Countries

France

Contacts

PRINCIPAL_INVESTIGATORVERDIER Marie-Clemence

Rennes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026